Clinical Trial Update: Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of atezolizumab with or without low-dose local radiation in relapsed/refractory advanced-stage follicular lymphoma was terminated; results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-01-12